Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues Earnings Results, Beats Expectations By $0.06 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) released its quarterly earnings results on Tuesday. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.06, Zacks reports. The business had revenue of $12.53 billion for the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.200-1.346 EPS.

Bayer Aktiengesellschaft Stock Down 0.1%

Shares of BAYRY stock traded down $0.02 during mid-day trading on Thursday, reaching $14.22. 188,960 shares of the company’s stock traded hands, compared to its average volume of 1,240,198. Bayer Aktiengesellschaft has a 12 month low of $7.31 and a 12 month high of $15.23. The company has a market cap of $55.88 billion, a P/E ratio of -27.88, a P/E/G ratio of 4.39 and a beta of 0.55. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06. The company’s 50-day moving average price is $12.49 and its 200-day moving average price is $12.11.

Analyst Ratings Changes

Several research firms have recently commented on BAYRY. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Finally, Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.